Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation

Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit the functions of viral HCMV glycoprotein B (gB)...

Descripción completa

Detalles Bibliográficos
Autores principales: Maertens, Johan, Logan, Aaron C., Jang, Junho, Long, Gwynn, Tang, Jih-Luh, Hwang, William Y. K., Koh, Liang Piu, Chemaly, Roy, Gerbitz, Armin, Winkler, Julia, Yeh, Su-Peng, Hiemenz, John, Christoph, Sandra, Lee, Dong-Gun, Wang, Po-Nan, Holler, Ernst, Mielke, Stephan, Akard, Luke, Yeo, Adeline, Ramachandra, Sangana, Smith, Kristin, Pertel, Peter, Segal, Florencia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179282/
https://www.ncbi.nlm.nih.gov/pubmed/32015031
http://dx.doi.org/10.1128/AAC.02467-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179282/
https://www.ncbi.nlm.nih.gov/pubmed/32015031
http://dx.doi.org/10.1128/AAC.02467-19

Ejemplares similares